Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Albuterol-induced downregulation of Gsα accounts for pulmonary β2-adrenoceptor desensitization in vivo
Paul A. Finney, … , Ian M. Adcock, Mark A. Giembycz
Paul A. Finney, … , Ian M. Adcock, Mark A. Giembycz
Published January 1, 2000
Citation Information: J Clin Invest. 2000;106(1):125-135. https://doi.org/10.1172/JCI8374.
View: Text | PDF
Article

Albuterol-induced downregulation of Gsα accounts for pulmonary β2-adrenoceptor desensitization in vivo

  • Text
  • PDF
Abstract

The aim of the present study was to develop a chronic in vivo model of pulmonary β2-adrenoceptor desensitization and to elucidate the nature and molecular basis of this state. Subcutaneous infusion of rats with albuterol for 7 days compromised the ability of albuterol, given acutely, to protect against acetylcholine-induced bronchoconstriction. The bronchoprotective effect of prostaglandin E2, but not forskolin, was also impaired, indicating that the desensitization was heterologous and that the primary defect in signaling was upstream of adenylyl cyclase. β2-Adrenoceptor density was reduced in lung membranes harvested from albuterol-treated animals, and this was associated with impaired albuterol-induced cyclic adenosine monophosphate (cAMP) accumulation and activation of cAMP-dependent protein kinase ex vivo. Gsα expression was reduced in the lung and tracheae of albuterol-treated rats, and cholera toxin–induced cAMP accumulation was blunted. Chronic treatment of rats with albuterol also increased cAMP phosphodiesterase activity and G protein–coupled receptor kinase-2, but the extent to which these events contributed to β2-adrenoceptor desensitization was unclear given that forskolin was active in both groups of animals and that desensitization was heterologous. Collectively, these results indicate that albuterol effects heterologous desensitization of pulmonary Gs-coupled receptors in this model, with downregulation of Gsα representing a primary molecular etiology.

Authors

Paul A. Finney, Maria G. Belvisi, Louise E. Donnelly, Tsu-Tshen Chuang, Judith C.W. Mak, Carol Scorer, Peter J. Barnes, Ian M. Adcock, Mark A. Giembycz

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Effect of chronic treatment of rats with albuterol on cAMP PDE activity ...
Effect of chronic treatment of rats with albuterol on cAMP PDE activity in lung. The ability of rolipram (30 μM; a), Org 9935 (30 μM; b), and a combination of rolipram and Org 9935 (c) to suppress cAMP hydrolysis was assessed in lung taken from rats treated chronically with saline and albuterol. Open and filled bars show PDE activity in the absence and presence of PDE inhibitor, respectively. In each panel, B/A corresponds to the fold-increase in activity attributable to the PDE isoenzyme(s) defined with rolipram, Org 9935, or rolipram/Org 9935. Total induction is given by (B + C + D)/(A + D). Data represent the mean ± SEM of eight determinations. EP < 0.05, significant inhibition of PDE activity.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts